GlassScriptPhysician profile
Nadeem Kandalaft
NPI 1891283081
$8,928.16
in general payments reported to CMS, 2019-2025
9 companies · $376 in 2025
The $376 reported for 2025 was more than what 76% of Diagnostic Radiology providers received nationally (typical 2025 total: $112).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $879 · 2023: $1,540 · 2024: $6,133 · 2025: $376.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $6,867 · Food and Beverage: $1,182.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $6,866.78 |
| Food and Beverage | $1,182.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inari Medical, INC. | $4,025.95 | 2023-2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Abbott Laboratories | $3,483.62 | 2023-2024 | Optis, Supera, Jeti |
| Terumo Medical Corporation | $1,034.36 | 2021-2025 | Azur Cx Detachable, Angio-Seal, Navicross |
| Stryker Corporation | $111.32 | 2025 | Flowtriever |
| Penumbra, INC. | $85.13 | 2025 | Ruby Coil |
| Medtronic, INC. | $54.14 | 2024 | Solitaire X, Valiant Captivia |
| Amgen INC. | $46.85 | 2023 | Repatha |
| Boston Scientific Corporation | $44.40 | 2024 | Therasphere Y90 Glass Microspheres 10 Gbq |
| Janssen Pharmaceuticals, INC | $42.39 | 2024 | Xarelto |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nadeem Kandalaft listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.